Anna Podolanczuk

Has grant

Assistant Professor of Medicine

Weill Cornell Medical College

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Anna Podolanczuk is an Assistant Professor of Medicine at Weill Cornell Medical College in the United States. Her research focuses on interstitial lung diseases, including the evaluation and management of interstitial lung abnormalities and the impact of biomarkers in these conditions. Recent publications highlight her work on enhancing equity in clinical trials and utilizing quantitative computed tomography for early detection of lung diseases.

Recent Grants

Grant: Close

Role of High Density Lipoproteins in Interstitial Lung Disease

Open Date: 2018-01-19

Close Date: 2022-12-31

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (13)

David Lederer

Regeneron Pharmaceuticals

UNITED STATES

View details

Professor

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anna Podolanczuk

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (26)

Associations of interstitial lung disease subtype and CT pattern with lung function and survival

Antinuclear antibodies and progression of quantitative interstitial lung changes: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study

Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities

Breaking Barriers: Enhancing Access, Equity, and Efficiency in Interstitial Lung Disease Clinical Trials

Oh to Be Watched Over by Machines of Loving Grace: Promise and Pitfalls of Quantitative Computed Tomography in Early Interstitial Lung Disease Detection

Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an AJRCCM Special Section

Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement

Prevalence of Interstitial Lung Abnormalities in Adult Smokers

Big Things Have Small Beginnings: Clinical Implications of Early Interstitial Lung Disease

Bystander No More: Small Airway Involvement in Idiopathic Pulmonary Fibrosis

Pioneering Research Driving Progress toward a Cure for Interstitial Lung Disease (ILD): Introduction to the AJRCCM Special Issue on ILD (Part 2)

The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions

Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era

Interventions to Improve Quality of Life and Knowledge in Hypersensitivity Pneumonitis

Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an AJRCCM Special Issue

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis

Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort

Radiographic Lung Abnormalities in First-Degree Relatives of Patients With Different Subtypes of Pulmonary Fibrosis

Obstructive Sleep Apnea and Longitudinal Changes in Interstitial Lung Imaging and Lung Function: The MESA Study

Idiopathic pulmonary fibrosis: state of the art for 2023

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.

Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the US and Canada

Update in Interstitial Lung Disease 2020

Lungs after COVID-19: Evolving Knowledge of Post–COVID-19 Interstitial Lung Disease

Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine

Collaborators (13)

David Lederer

RILEY HANNAN

Martin Kolb

John Kim

Eric Hoffman

Justin M. Oldham

Gary Hunninghake

Jonathan Tobin

Margaret Salisbury

David Zhang

Kerri Johannson

Robert Kaner

Susan Murray

Make your next move.